[ CAS No. 25341-42-8 ] {[proInfo.proName]}

Name: 25341-42-8|(S)-2-(((Benzyloxy)carbonyl)amino)-3-cyclohexylpropanoic acid|95%
Brand: Ambeed
SKU: A108538
Price: 14.0 USD
Availability: InStock
Rating: 92 (29 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 25341-42-8 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 25341-42-8 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 25341-42-8 ]

SDS Specification

Alternatived Products of [ 25341-42-8 ]

Product Details of [ 25341-42-8 ]

CAS No. :	25341-42-8	MDL No. :	MFCD00191081
Formula :	C₁₇H₂₃NO₄	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	MNABZONTQXNLDT-HNNXBMFYSA-N
M.W :	305.37	Pubchem ID :	14158015
Synonyms :

Safety of [ 25341-42-8 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P280-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 25341-42-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 25341-42-8 ]
Downstream synthetic route of [ 25341-42-8 ]

[ 25341-42-8 ] Synthesis Path-Upstream 1~11

1
[ 25341-42-8 ]
[ 27527-05-5 ]

Reference： [1] Organic and Biomolecular Chemistry, 2004, vol. 2, # 24, p. 3584 - 3587

2
[ 27527-05-5 ]
[ 501-53-1 ]
[ 25341-42-8 ]

Yield	Reaction Conditions	Operation in experiment
95%	With potassium carbonate In tetrahydrofuran; water at 0 - 20℃;	To a O9C solution of 3-cyclohexyl-L-alanine (10g, 58.4mmol) in THF/ H2O ( 1/1 , 292ml) was added benzyl chloroformate (9.93 g, 58.4 mmol) and K2CO3 (9.67g, 70.09 mmol). The mixture was stirred at 0s C for 0.5 hour, and then stirred overnight at RT. The reaction mixture was diluted with EtOAc (200ml) and adjusted the pH to about 2 with 6 N HCI. The organic layer was washed with brine, dried (MgSO4), filtered and concentrated to a solid as product in 95percent yield (17g): MS (m/z): 306(M+H).

Reference： [1] Patent: WO2006/29210, 2006, A2, . Location in patent: Page/Page column 47

3
[ 4441-50-3 ]
[ 501-53-1 ]
[ 25341-42-8 ]

Reference： [1] Patent: US5145951, 1992, A,

4
[ 17193-39-4 ]
[ 25341-42-8 ]

Reference： [1] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 1, p. 62 - 65
[2] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 21, p. 5941 - 5944
[3] Journal of Medicinal Chemistry, 2015, vol. 58, # 7, p. 3144 - 3155

5
[ 7647-01-0 ]
[ 113828-93-6 ]
[ 25341-42-8 ]

Reference： [1] Journal of Medicinal Chemistry, 2015, vol. 58, # 7, p. 3144 - 3155

6
[ 163085-09-4 ]
[ 25341-42-8 ]

Reference： [1] Organic and Biomolecular Chemistry, 2004, vol. 2, # 24, p. 3584 - 3587

7
[ 626-62-0 ]
[ 25341-42-8 ]

Reference： [1] Organic and Biomolecular Chemistry, 2004, vol. 2, # 24, p. 3584 - 3587

8
[ 163084-89-7 ]
[ 25341-42-8 ]

Reference： [1] Organic and Biomolecular Chemistry, 2004, vol. 2, # 24, p. 3584 - 3587

9
[ 40203-89-2 ]
[ 25341-42-8 ]

Reference： [1] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 1, p. 62 - 65
[2] Journal of Medicinal Chemistry, 2015, vol. 58, # 7, p. 3144 - 3155

10
[ 113828-93-6 ]
[ 25341-42-8 ]

Reference： [1] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 1, p. 62 - 65
[2] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 21, p. 5941 - 5944

11
[ 27527-05-5 ]
[ 25341-42-8 ]

Reference： [1] Journal of Medicinal Chemistry, 2015, vol. 58, # 7, p. 3144 - 3155

[ 25341-42-8 ] Synthesis Path-Downstream 1~84

1
[ 6638-79-5 ]
[ 25341-42-8 ]
[ 118388-23-1 ]

Reference： [1]Tetrahedron,1993,vol. 49,p. 8739 - 8756

2
[ 25341-42-8 ]
[ 113828-85-6 ]

Reference： [1]Tetrahedron Letters,1992,vol. 33,p. 4257 - 4260

3
[ 6346-09-4 ]
[ 25341-42-8 ]
[(S)-2-Cyclohexyl-1-(4,4-diethoxy-butylcarbamoyl)-ethyl]-carbamic acid benzyl ester [ No CAS ]

Reference： [1]Tetrahedron Letters,1995,vol. 36,p. 3755 - 3758

4
[ 123-75-1 ]
[ 25341-42-8 ]
1-[N-(benzyloxycarbonyl)-(L-cyclohexylalanyl)]pyrrolidine [ No CAS ]

Reference： [1]European Journal of Medicinal Chemistry,1997,vol. 32,p. 300 - 310

5
[ 25341-42-8 ]
Ser(tBu)-NH₂ [ No CAS ]
[ 211755-74-7 ]

Reference： [1]Arzneimittel-Forschung/Drug Research,1998,vol. 48,p. 709 - 712

6
[ 25341-42-8 ]
[(S)-1-((S)-1-Amino-2-hydroxy-ethylcarbamoyl)-2-cyclohexyl-ethyl]-carbamic acid benzyl ester [ No CAS ]
[ 211755-60-1 ]

Reference： [1]Arzneimittel-Forschung/Drug Research,1998,vol. 48,p. 709 - 712

7
[ 25341-42-8 ]
[ 124-40-3 ]
[ 609367-22-8 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2003,vol. 13,p. 2715 - 2718

8
[ 25341-42-8 ]
[ 27527-05-5 ]

Reference： [1]Organic and Biomolecular Chemistry,2004,vol. 2,p. 3584 - 3587

9
[ 163085-09-4 ]
[ 25341-42-8 ]

Reference： [1]Organic and Biomolecular Chemistry,2004,vol. 2,p. 3584 - 3587

10
[ 626-62-0 ]
[ 25341-42-8 ]

Reference： [1]Organic and Biomolecular Chemistry,2004,vol. 2,p. 3584 - 3587

11
[ 163084-89-7 ]
[ 25341-42-8 ]

Reference： [1]Organic and Biomolecular Chemistry,2004,vol. 2,p. 3584 - 3587

12
[ 25341-42-8 ]
[ 609367-36-4 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2003,vol. 13,p. 2715 - 2718

13
[ 25341-42-8 ]
2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic Acid (2-Cyclohexyl-1S-dimethyl-carbamoyl-ethyl)-amide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2003,vol. 13,p. 2715 - 2718

14
[ 25341-42-8 ]
[ 609366-97-4 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2003,vol. 13,p. 2715 - 2718

15
[ 25341-42-8 ]
(S)-2-Amino-N-((S)-1-amino-2-hydroxy-ethyl)-3-cyclohexyl-propionamide [ No CAS ]

Reference： [1]Arzneimittel-Forschung/Drug Research,1998,vol. 48,p. 709 - 712

16
[ 25341-42-8 ]
[(S)-1-((S)-1-Amino-2-hydroxy-ethylcarbamoyl)-2-cyclohexyl-ethyl]-carbamic acid benzyl ester [ No CAS ]

Reference： [1]Arzneimittel-Forschung/Drug Research,1998,vol. 48,p. 709 - 712

17
[ 25341-42-8 ]
[ 1026371-09-4 ]

Reference： [1]Arzneimittel-Forschung/Drug Research,1998,vol. 48,p. 709 - 712

18
[ 25341-42-8 ]
[(S)-1-((S)-1-Amino-2-tert-butoxy-ethylcarbamoyl)-2-cyclohexyl-ethyl]-carbamic acid benzyl ester [ No CAS ]

Reference： [1]Arzneimittel-Forschung/Drug Research,1998,vol. 48,p. 709 - 712

19
[ 25341-42-8 ]
[(S)-1-((R)-1-Benzyloxycarbonylamino-2-hydroxy-ethylcarbamoyl)-2-cyclohexyl-ethyl]-carbamic acid benzyl ester [ No CAS ]

Reference： [1]Arzneimittel-Forschung/Drug Research,1998,vol. 48,p. 709 - 712

20
[ 25341-42-8 ]
[ 211755-60-1 ]

Reference： [1]Arzneimittel-Forschung/Drug Research,1998,vol. 48,p. 709 - 712

21
[ 25341-42-8 ]
{(S)-2-Cyclohexyl-1-[(R)-1-(9H-fluoren-9-ylmethoxycarbonylamino)-2-hydroxy-ethylcarbamoyl]-ethyl}-carbamic acid 9H-fluoren-9-ylmethyl ester [ No CAS ]

Reference： [1]Arzneimittel-Forschung/Drug Research,1998,vol. 48,p. 709 - 712

22
[ 25341-42-8 ]
((S)-2-Cyclohexyl-1-{1-[(S)-3-cyclohexyl-2-(9H-fluoren-9-ylmethoxycarbonylamino)-propionylamino]-2-hydroxy-ethylcarbamoyl}-ethyl)-carbamic acid 9H-fluoren-9-ylmethyl ester [ No CAS ]

Reference： [1]Arzneimittel-Forschung/Drug Research,1998,vol. 48,p. 709 - 712

23
[ 25341-42-8 ]
1-(L-cyclohexylalanyl)pyrrolidine [ No CAS ]

Reference： [1]European Journal of Medicinal Chemistry,1997,vol. 32,p. 300 - 310

24
[ 25341-42-8 ]
[ 105852-47-9 ]

Reference： [1]Tetrahedron,1993,vol. 49,p. 8739 - 8756
[2]Tetrahedron Letters,1992,vol. 33,p. 4257 - 4260

25
[ 25341-42-8 ]
[ 151337-14-3 ]

Reference： [1]Tetrahedron,1993,vol. 49,p. 8739 - 8756

26
[ 25341-42-8 ]
(2S,3R) 3-cyclohexylmethyl-2-(2-isopropylpropen-2-yl)-2,3,5-tetrahydro-4H-oxazole 5-one [ No CAS ]

Reference： [1]Tetrahedron,1993,vol. 49,p. 8739 - 8756

27
[ 25341-42-8 ]
(2S,3S) 3-cyclohexylmethyl-2-(2-isopropylpropen-2-yl)-2,3,5-tetrahydro-4H-oxazole 5-one [ No CAS ]

Reference： [1]Tetrahedron,1993,vol. 49,p. 8739 - 8756

28
[ 25341-42-8 ]
[ 151337-13-2 ]

Reference： [1]Tetrahedron,1993,vol. 49,p. 8739 - 8756

29
[ 25341-42-8 ]
[ 151337-12-1 ]

Reference： [1]Tetrahedron,1993,vol. 49,p. 8739 - 8756

30
[ 25341-42-8 ]
[ 143914-93-6 ]

Reference： [1]Tetrahedron Letters,1992,vol. 33,p. 4257 - 4260

31
[ 25341-42-8 ]
[ 143914-92-5 ]

Reference： [1]Tetrahedron Letters,1992,vol. 33,p. 4257 - 4260

32
[ 25341-42-8 ]
[ 143915-11-1 ]

Reference： [1]Tetrahedron Letters,1992,vol. 33,p. 4257 - 4260

33
[ 25341-42-8 ]
[ 143915-10-0 ]

Reference： [1]Tetrahedron Letters,1992,vol. 33,p. 4257 - 4260

34
[ 25341-42-8 ]
[ 143915-09-7 ]

Reference： [1]Tetrahedron Letters,1992,vol. 33,p. 4257 - 4260

35
[ 25341-42-8 ]
[ 143915-08-6 ]

Reference： [1]Tetrahedron Letters,1992,vol. 33,p. 4257 - 4260

36
[ 186581-53-3 ]
[ 80-11-5 ]
[ 25341-42-8 ]
[ 543-27-1 ]
[ 118387-40-9 ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethylmorpholine;; In tetrahydrofuran; diethyl ether;	(i) A solution of 19.6 g of <strong>[25341-42-8]N-(benzyloxycarbonyl)-3-cyclohexyl-L-alanine</strong> in 60 ml of tetrahydrofuran was cooled to -10 C. and 8.9 ml of N-ethylmorpholine were added. 11.6 ml of isobutyl chloroformate were added dropwise and the mixture was stirred at -10 C. for a further 15 minutes. 250 ml of diethyl ether were added and the mixture was filtered. The filtrate was added to a cold solution of diazomethane in diethyl ether (prepared from 21.5 g of N-methyl-N-nitroso-4-toluenesulphonamide) and the mixture was stirred at room temperature for 1.5 hours. The solution was then washed with two 200 ml portions of water and with 200 ml of saturated sodium bicarbonate solution, dried over anhydrous sodium sulphate and evaporated to give 6.6 g of benzyl [2-cyclohexyl-1(S)-(2-diazoacetyl)ethyl] carbamate as a yellow oil which was used without further purification.

Reference： [1]Patent: US5157041,1992,A

37
[ 4441-50-3 ]
[ 501-53-1 ]
[ 25341-42-8 ]

Yield	Reaction Conditions	Operation in experiment
	With hydrogenchloride; In 1,4-dioxane; sodium hydroxide; diethyl ether; water; ethyl acetate;	N-(Benzyloxycarbonyl)-2(S)-amino-3-cyclohexylpropionic acid STR18 290 g (1.7 mol) of 2-amino-3-cyclohexylpropionic acid are dissolved in 375 ml of 4N NaOH. The solution is made up to 2 l with water and 500 ml of dioxane are added. 255 ml (1.7 mol) of benzyloxycarbonyl chloride are added dropwise at pH 10 under pH-state conditions. After 8 h, the solution is extracted twice using diethyl ether and acidified to pH 2 using 1N hydrochloric acid. The product is extracted 3 times using 200 ml of ethyl acetate each time. After washing the organic extract, drying over sodium sulphate and concentrating, 5 g of the title compound are obtained. TLC: Rf (IIIa)=0.81 (TDM)* MS (EI): 305

Reference： [1]Patent: US5145951,1992,A

38
[ 25341-42-8 ]
[ 105852-46-8 ]

Yield	Reaction Conditions	Operation in experiment
	With thionyl chloride; In ethanol; toluene;	(c) 2(S)-Benzyloxycarbonylamino-3-cyclohexylpropionic acid ethyl ester 243 g of 2(S)-benzyloxycarbonylamino-3-cyclohexylpropionic acid (for manufacture see Helvetica Chimica Acta 57, 2131 (1974)) are placed in 600 ml of toluene and 900 ml of ethanol. The reaction is cooled to 0 and 88.3 g of thionyl chloride are added dropwise within a period of 30 minutes. Cooling is discontinued and the reaction mixture is stirred for 18 hours. The reaction mixture is filtered and the filtrate is concentrated. The residue is separated by flash cromatography (Lobar (2 kg of silica gel 60, 40-63 mum, eluant N5). The product-containing fractions are combined, concentrated by evaporation and dried in a high vacuum. The title compound is obtained in the form of a slightly yellowish oil. Rf (N5)=0.2; Rf (N15)=0.52.
	With thionyl chloride; In ethanol; toluene;	(a) 2(S)-benzyloxycarbonylamino-3-cyclohexyl-propionic acid ethyl ester: 243 g of 2(S)-benzyloxycarbonylamino-3-cyclohexylpropionic acid (manufacture: Helvetica Chimica Acta 57, 2131(1974)) are placed in 600 ml of toluene and 900 ml of ethanol. The reaction mixture is cooled to 0 and 88.3 g of thionyl chloride are added dropwise within 30 minutes. The cooling is removed and the mixture is stirred for 18 hours. The reaction mixture is filtered and the filtrate is concentrated. The residue is separated by means of flash chromatography (2 kg of silica gel 60,40-63 mum, eluant F) The product containing fractions are combined, concentrated by evaporation and dried under a high vacuum. The title compound is obtained in the form of a slightly yellowish oil. Rf (F)=0.2; Rf (B)=0.52.

Reference： [1]Patent: US4727060,1988,A
[2]Patent: US4758584,1988,A

39
[ 25341-42-8 ]
[ 150349-36-3 ]
[ 878798-77-7 ]

Yield	Reaction Conditions	Operation in experiment
62%	With 4-methyl-morpholine; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; 3-hydroxy-3,4-dihydrobenzotriazine-4-one; In dichloromethane; at 20℃;	To a dichloromethane solution of 3-cyclohexyl-Lambda/-[(phenylmethyl)oxy]carbonyl}-L- alanine (8.92 g, 29.26 mmol) was added 1 ,1 -dimethyl ethyl (3-aminopropyl)carbamate (5g g, 26.60 mmol), HOOBT (86.7 mg, 0.532 mmol), and NMM (4.4ml, 39.9 mmol). The mixture was stirred several minutes whereupon EDCHCI (6.12 g, 31.91 mmol) was added. The reaction mixture was stirred overnight at RT. The solution was washed with 10% citric acid and brine, dried (MgSO4), filtered and concentrated to a solid. Purification by silica gel column chromatography (30%-90% ethyl acetate/hexane) gave the product as a white solid in 62% yield (7.8g): MS (m/z): 476(M+H).

Reference： [1]Patent: WO2006/29210,2006,A2 .Location in patent: Page/Page column 48

40
[ 27527-05-5 ]
[ 501-53-1 ]
[ 25341-42-8 ]

Yield	Reaction Conditions	Operation in experiment
95%	With potassium carbonate; In tetrahydrofuran; water; at 0 - 20℃;	To a O9C solution of 3-cyclohexyl-L-alanine (10g, 58.4mmol) in THF/ H2O ( 1/1 , 292ml) was added benzyl chloroformate (9.93 g, 58.4 mmol) and K2CO3 (9.67g, 70.09 mmol). The mixture was stirred at 0s C for 0.5 hour, and then stirred overnight at RT. The reaction mixture was diluted with EtOAc (200ml) and adjusted the pH to about 2 with 6 N HCI. The organic layer was washed with brine, dried (MgSO4), filtered and concentrated to a solid as product in 95% yield (17g): MS (m/z): 306(M+H).

Reference： [1]Patent: WO2006/29210,2006,A2 .Location in patent: Page/Page column 47

41
[ 141-43-5 ]
[ 25341-42-8 ]
[ 768366-82-1 ]

Yield	Reaction Conditions	Operation in experiment
28%		(S)-2-Benzyloxycarbonylamino-3-cyclohexyl-propionic acid 1 (2.065 g, 6.77 mmol, 1.0 eq.) was dissolved in CH2Cl2 (50 mL). N-(3-Dimethylaminopropyl)-N'-ethyl-carbodiimide hydrochloride (EDC, 1.56 g, 8.11 mmol, 1.2 eq.) and 1-Hydroxybenzotriazole hydrate (HOBT, 1.10 g, 8.16 mmol, 1.2 eq.) were added to the reaction slurry. After 20 minutes, ethanolamine (1.6 mL, 26.58 mmol, 3.9 eq.) was added via syringe and the reaction was allowed to stir at room temperature and monitored by LC/MS. After the reaction was allowed to proceed to completion, the reaction mixture was extracted with water (40 mL), 1M HCl (30 mL), followed by saturated NaHCO3 and saturated NaCl. The organic layer was dried over MgSO4 and filtered. The organic solvent was removed in vacuo and purified by silica gel chromatography to yield (S)-[2-Cyclohexyl-1-(2-hydroxy-ethylcarbamoyl)-ethyl]-carbamic acid benzyl ester 2 (780 mg, 2.24 mmol, 28%) as a white solid: 1H-NMR (400 MHz, CDCl3) delta 0.76-0.92 (m, 2H), 1.02-1.35 (m, 4H), 1.44-1.73 (m, 7H), 3.17-3.25 (m, 1H), 3.34-3.40 (m, 1H), 3.51-3.69 (m, 3H), 4.24 (dt, 1H, J=8.8 Hz, 5.6 Hz), 4.94 (d, 1H, J=12.0 Hz), 5.07 (d, 1H, J=12.0 Hz), 5.93 (1H, J=12.0 Hz), 7.24-7.30 (m, 5H).

Reference： [1]Patent: US2004/198780,2004,A1 .Location in patent: Page 24-25

42
[ 25341-42-8 ]
C₁₇H₂₂ClNO₃ [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2011,vol. 54,p. 396 - 400

43
[ 25341-42-8 ]
[ 1259946-44-5 ]

Reference： [1]Journal of Medicinal Chemistry,2011,vol. 54,p. 396 - 400

44
[ 25341-42-8 ]
[ 1259945-78-2 ]

Reference： [1]Journal of Medicinal Chemistry,2011,vol. 54,p. 396 - 400

45
[ 1385184-01-9 ]
[ 25341-42-8 ]
[ 1416992-20-5 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2013,vol. 23,p. 62 - 65
[2]Bioorganic and Medicinal Chemistry Letters,2013,vol. 23,p. 5941 - 5944
[3]Journal of Medicinal Chemistry,2015,vol. 58,p. 3144 - 3155

46
[ 17193-39-4 ]
[ 25341-42-8 ]

47
[ 113828-93-6 ]
[ 25341-42-8 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2013,vol. 23,p. 62 - 65

48
[ 25341-42-8 ]
[ 1416992-27-2 ]

49
[ 25341-42-8 ]
[ 1416992-34-1 ]

50
[ 25341-42-8 ]
[ 1416992-42-1 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2013,vol. 23,p. 62 - 65
[2]Journal of Medicinal Chemistry,2015,vol. 58,p. 3144 - 3155

51
[ 40203-89-2 ]
[ 25341-42-8 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2013,vol. 23,p. 62 - 65
[2]Journal of Medicinal Chemistry,2015,vol. 58,p. 3144 - 3155

52
[ 25341-42-8 ]
[ 1429340-61-3 ]

Reference： [1]Journal of Organic Chemistry,2013,vol. 78,p. 3655 - 3675

53
[ 25341-42-8 ]
[ 1429340-62-4 ]

Reference： [1]Journal of Organic Chemistry,2013,vol. 78,p. 3655 - 3675

54
[ 25341-42-8 ]
C₂₈H₄₈N₄O₅*C₂HF₃O₂ [ No CAS ]

Reference： [1]Journal of Organic Chemistry,2013,vol. 78,p. 3655 - 3675

55
[ 25341-42-8 ]
[ 1429340-65-7 ]

Reference： [1]Journal of Organic Chemistry,2013,vol. 78,p. 3655 - 3675

56
[ 25341-42-8 ]
[ 1445578-74-4 ]

Reference： [1]Journal of Organic Chemistry,2013,vol. 78,p. 3655 - 3675

57
[ 25341-42-8 ]
[ 1445578-68-6 ]

Reference： [1]Journal of Organic Chemistry,2013,vol. 78,p. 3655 - 3675

58
[ 25341-42-8 ]
[ 1429340-68-0 ]

Reference： [1]Journal of Organic Chemistry,2013,vol. 78,p. 3655 - 3675

59
[ 25341-42-8 ]
[ 2812-46-6 ]
[ 1445579-13-4 ]

Reference： [1]Journal of Organic Chemistry,2013,vol. 78,p. 3655 - 3675

60
[ 25341-42-8 ]
[ 1467641-79-7 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2013,vol. 23,p. 5941 - 5944

61
[ 25341-42-8 ]
[ 1467641-81-1 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2013,vol. 23,p. 5941 - 5944

62
[ 25341-42-8 ]
[ 1467641-83-3 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2013,vol. 23,p. 5941 - 5944

63
[ 25341-42-8 ]
[ 1467641-85-5 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2013,vol. 23,p. 5941 - 5944

64
[ 25341-42-8 ]
[ 1467641-87-7 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2013,vol. 23,p. 5941 - 5944

65
(S)-3-Cyclohexyl-2-trichloromethoxycarbonylamino-propionic acid methyl ester [ No CAS ]
[ 25341-42-8 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2013,vol. 23,p. 5941 - 5944

66
[ 2627-75-0 ]
[ 25341-42-8 ]
4-chloro-2-[(4-bromophenyl)carbamoyl]phenyl (2S)-2-[(benzyloxy)carbonyl]amino}-3-cyclohexylpropanoate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
43%	With dicyclohexyl-carbodiimide; In N,N-dimethyl-formamide; at -10℃; for 4h;	General procedure: N-Benzyloxycarbonyl protected amino acid (0.01 mol) and substituted salicylanilide 3 (0.01 mol) were dissolved in dry DMF (45 mL). The solution was cooled to -10 C, and N,N-dicyclohexylcarbodiimide (0.011 equiv) was added in three portions for more than 1 h. The mixture was then stirred for 3 h at the same temperature and stored at 4 C for 20 h. Precipitated N,N-dicyclohexylurea was removed by filtration, and the solvent was evaporated in vacuo. The crude product was crystallized from ethyl acetate-hexane.

Reference： [1]Bioorganic and Medicinal Chemistry,2013,vol. 21,p. 6574 - 6581

67
[ 27527-05-5 ]
[ 25341-42-8 ]

Reference： [1]Journal of Medicinal Chemistry,2015,vol. 58,p. 3144 - 3155

68
[ 7647-01-0 ]
[ 113828-93-6 ]
[ 25341-42-8 ]

Reference： [1]Journal of Medicinal Chemistry,2015,vol. 58,p. 3144 - 3155

69
[ 25341-42-8 ]
methyl 2-[(1S)-1-[(benzyloxy)carbonyl]amino}-2-cyclohexylethyl]-1-methyl-1H-1,3-benzodiazole-6-carboxylate [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2017,vol. 25,p. 1787 - 1794

70
[ 25341-42-8 ]
methyl 2-[(1S)-2-cyclohexyl-1-{2-[(4-phenoxyphenyl)amino]acetamido}ethyl]-1-methyl-1H-1,3-benzodiazole-6-carboxylate [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2017,vol. 25,p. 1787 - 1794

71
[ 25341-42-8 ]
methyl 2-[(1S)-2-cyclohexyl-1-[2,5-dioxo-3-(4-phenoxyphenyl)imidazolidin-1-yl]ethyl]-1-methyl-1H-1,3-benzodiazole-6-carboxylate [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2017,vol. 25,p. 1787 - 1794

72
[ 25341-42-8 ]
2-[(1S)-2-cyclohexyl-1-[2,5-dioxo-3-(4-phenoxyphenyl)imidazolidin-1-yl]ethyl]-1-methyl-1H-1,3-benzodiazole-6-carboxylic acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2017,vol. 25,p. 1787 - 1794

73
[ 616224-38-5 ]
[ 25341-42-8 ]
methyl 4-[(2S)-2-[(benzyloxy)carbonyl]amino}-3-cyclohexylpropanamido]-3-(methylamino)benzoate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
50%	With 1-hydroxy-7-aza-benzotriazole; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; trimethylamine; In N,N-dimethyl-formamide; at -20 - 0℃; for 15h;	General procedure: To a solution of Z-Leu-OH (350 mg, 1.32 mmol) in DMF (3 ml), methyl 4-amino-3-(methylamino)benzoatee [3] (334 mg, 1.32 mmol) in DMF (2 ml) and trimethylamine (462 mul, 3.30 mmol) were added at 0 . Subsequently, HOAt (269 mg, 1.98 mmol) and WSCI.HCl (380 mg, 1.98 mmol) were added to the former solution at -20 C and stirred for 15 h at ambient temperature. The reaction mixture was quenched with sat.NH4Cl and extracted with EtOAc. The combined extracts were washed with water and brine, dried over MgSO4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give 278 mg of 1a

Reference： [1]Bioorganic and Medicinal Chemistry,2017,vol. 25,p. 1787 - 1794

74
[ 25341-42-8 ]
benzyl (S)-2-cyclohexyl-1-(4-phenyl-1H-imidazol-2-yl)ethylcarbamate [ No CAS ]

Reference： [1]Synthesis,2019,vol. 51,p. 1961 - 1968
[2]MedChemComm,2019,vol. 10,p. 1838 - 1843

75
[ 25341-42-8 ]
benzyl (S)-2-cyclohexyl-1-(4-(2-thienyl)-1H-imidazol-2-yl)ethylcarbamate [ No CAS ]

Reference： [1]Synthesis,2019,vol. 51,p. 1961 - 1968

76
[ 2114-00-3 ]
[ 25341-42-8 ]
(R)-1-oxo-1-phenylpropan-2-yl (S)-2-(benzyloxycarbonylamino)-3-cyclohexylpropanoate [ No CAS ]
(S)-1-oxo-1-phenylpropan-2-yl (S)-2-(benzyloxycarbonylamino)-3-cyclohexylpropanoate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		General procedure: (S)-2-(Benzyloxycarbonylamino)-3-cyclohexylpropanoic acid (1; 3.05g, 10 mmol) or (R)-2-(benzyloxycarbonylamino)-3-cyclohexylpropanoicacid (2; 3.05 g, 10 mmol) was dissolved in anhydrous DMF (25mL) and K2CO3 (1.66 g, 12 mmol) was added. After 10 min of stirringat room temperature, the respective alkylating agent was added (11mmol) and the reaction mixture was stirred at room temperature fora further 4 h. The mixture was then diluted with H2O (60 mL) and extractedwith EtOAc (120 mL). The organic layer was dried usingNa2SO4, filtered, and evaporated to dryness. The residue was purifiedby column chromatography on silica gel.

Reference： [1]Synthesis,2019,vol. 51,p. 1961 - 1968

77
[ 25341-42-8 ]
[ 1484-50-0 ]
(R)-2-oxo-1,2-diphenylethyl (S)-2-(benzyloxycarbonylamino)-3-cyclohexylpropanoate [ No CAS ]
(S)-2-oxo-1,2-diphenylethyl (S)-2-(benzyloxycarbonylamino)-3-cyclohexylpropanoate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		General procedure: (S)-2-(Benzyloxycarbonylamino)-3-cyclohexylpropanoic acid (1; 3.05g, 10 mmol) or (R)-2-(benzyloxycarbonylamino)-3-cyclohexylpropanoicacid (2; 3.05 g, 10 mmol) was dissolved in anhydrous DMF (25mL) and K2CO3 (1.66 g, 12 mmol) was added. After 10 min of stirringat room temperature, the respective alkylating agent was added (11mmol) and the reaction mixture was stirred at room temperature fora further 4 h. The mixture was then diluted with H2O (60 mL) and extractedwith EtOAc (120 mL). The organic layer was dried usingNa2SO4, filtered, and evaporated to dryness. The residue was purifiedby column chromatography on silica gel.

Reference： [1]Synthesis,2019,vol. 51,p. 1961 - 1968

78
[ 25341-42-8 ]
[ 70-11-1 ]
2-oxo-2-phenylethyl (S)-2-(benzyloxycarbonylamino)-3-cyclohexylpropanoate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
82%		General procedure: (S)-2-(Benzyloxycarbonylamino)-3-cyclohexylpropanoic acid (1; 3.05g, 10 mmol) or (R)-2-(benzyloxycarbonylamino)-3-cyclohexylpropanoicacid (2; 3.05 g, 10 mmol) was dissolved in anhydrous DMF (25mL) and K2CO3 (1.66 g, 12 mmol) was added. After 10 min of stirringat room temperature, the respective alkylating agent was added (11mmol) and the reaction mixture was stirred at room temperature fora further 4 h. The mixture was then diluted with H2O (60 mL) and extractedwith EtOAc (120 mL). The organic layer was dried usingNa2SO4, filtered, and evaporated to dryness. The residue was purifiedby column chromatography on silica gel. 2-Oxo-2-phenylethyl (S)-2-(Benzyloxycarbonylamino)-3-cyclohexylpropanoate(3)From 2-bromoacetophenone (2.19 g). Column chromatography withpetroleum ether/EtOAc, 20:1 to 10:1.Yield: 3.47 g (82%, 8.20 mmol); colorless crystals; mp 87-90 C.1H NMR (600 MHz, DMSO-d6): = 0.80-0.89 (m, 1 H, Cy-H), 0.90-0.99(m, 1 H, Cy-H), 1.09-1.24 (m, 2 H, Cy-H), 1.37-1.46 (m, 1 H, Cy-H),1.57-1.77 (m, 8 H, CH2-Cy, Cy-H), 4.25 (ddd, J = 10.4, 8.0, 4.6 Hz, 1 H,CH-CH2-Cy), 5.03 (d, J = 12.8 Hz, 1 H, CH2-C6H5), 5.06 (d, J = 12.5 Hz, 1H, CH2-C6H5), 5.45 (d, J = 16.8 Hz, 1 H, CH2-CO-C6H5), 5.57 (d, J = 16.9Hz, 1 H, CH2-CO-C6H5), 7.28-7.37 (m, 5 H, CH2-C6H5), 7.53-7.57 (m, 2H, CH2-CO-C6H5), 7.66-7.70 (m, 1 H, CH2-CO-C6H5), 7.78 (d, J = 8.1 Hz,1 H, NH), 7.93-7.97 (m, 2 H, CH2-CO-C6H5).13C NMR (150 MHz, DMSO-d6): = 25.74 (Cy-C), 25.96 (Cy-C), 26.18(Cy-C), 31.56 (Cy-C), 33.34 (Cy-C), 33.63 (Cy-C), 38.33 (CH2-Cy), 51.62(CH-CH2-Cy), 65.63 (CH2-C6H5), 66.87 (CH2-CO-C6H5), 127.79 (CH2-C6H5), 127.95 (CH2-CO-C6H5), 127.97 (CH2-C6H5), 128.51 (CH2-C6H5),129.07 (CH2-CO-C6H5), 134.00 (CH2-CO-C6H5), 134.13 (CH2-CO-C6H5),137.15 (CH2-C6H5), 156.30 (O-CO-NH), 172.69 (CO-OCH2), 192.71(CH2-CO-C6H5).LC/MS (ESI): 92.6% purity; m/z = 424.3 [M + H]+, 441.2 [M + NH4]+.HRMS (ESI): m/z [M + H]+ calcd for C25H29NO5: 424.2118; found:424.2138.

Reference： [1]Synthesis,2019,vol. 51,p. 1961 - 1968
[2]MedChemComm,2019,vol. 10,p. 1838 - 1843

79
[ 10531-41-6 ]
[ 25341-42-8 ]
2-oxo-2-(2-thienyl)ethyl (S)-2-(benzyloxycarbonylamino)-3-cyclohexylpropanoate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
77%		General procedure: (S)-2-(Benzyloxycarbonylamino)-3-cyclohexylpropanoic acid (1; 3.05g, 10 mmol) or (R)-2-(benzyloxycarbonylamino)-3-cyclohexylpropanoicacid (2; 3.05 g, 10 mmol) was dissolved in anhydrous DMF (25mL) and K2CO3 (1.66 g, 12 mmol) was added. After 10 min of stirringat room temperature, the respective alkylating agent was added (11mmol) and the reaction mixture was stirred at room temperature fora further 4 h. The mixture was then diluted with H2O (60 mL) and extractedwith EtOAc (120 mL). The organic layer was dried usingNa2SO4, filtered, and evaporated to dryness. The residue was purifiedby column chromatography on silica gel.

Reference： [1]Synthesis,2019,vol. 51,p. 1961 - 1968

80
[ 17694-68-7 ]
[ 25341-42-8 ]
2-oxo-2-(pyridin-3-yl)ethyl (S)-2-(benzyloxycarbonylamino)-3-cyclohexylpropanoate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
74%		General procedure: (S)-2-(Benzyloxycarbonylamino)-3-cyclohexylpropanoic acid (1; 3.05g, 10 mmol) or (R)-2-(benzyloxycarbonylamino)-3-cyclohexylpropanoicacid (2; 3.05 g, 10 mmol) was dissolved in anhydrous DMF (25mL) and K2CO3 (1.66 g, 12 mmol) was added. After 10 min of stirringat room temperature, the respective alkylating agent was added (11mmol) and the reaction mixture was stirred at room temperature fora further 4 h. The mixture was then diluted with H2O (60 mL) and extractedwith EtOAc (120 mL). The organic layer was dried usingNa2SO4, filtered, and evaporated to dryness. The residue was purifiedby column chromatography on silica gel.

Reference： [1]Synthesis,2019,vol. 51,p. 1961 - 1968

81
[ 25341-42-8 ]
(S)-ethyl 2-(2-(1-(benzyloxycarbonylamino)-2-cyclohexylethyl)-4-phenyl-1H-imidazol-1-yl)acetate [ No CAS ]

Reference： [1]MedChemComm,2019,vol. 10,p. 1838 - 1843

82
[ 25341-42-8 ]
(S)-8-(cyclohexylmethyl)-2-phenyl-7,8-dihydroimidazo[1,2-a]pyrazin-6(5H)-one [ No CAS ]

Reference： [1]MedChemComm,2019,vol. 10,p. 1838 - 1843

83
[ 25341-42-8 ]
(S)-ethyl 3-(2-(1-(benzyloxycarbonylamino)-2-cyclohexylethyl)-4-phenyl-1H-imidazol-1-yl)propanoate [ No CAS ]

Reference： [1]MedChemComm,2019,vol. 10,p. 1838 - 1843

84
[ 25341-42-8 ]
(S)-9-(cyclohexylmethyl)-2-phenyl-8,9-dihydro-5H-imidazo[1,2-a][1,4]diazepin-7(6H)-one [ No CAS ]

Reference： [1]MedChemComm,2019,vol. 10,p. 1838 - 1843

Same Skeleton Products

Related Products

Historical Records

Similar Product of
[ 25341-42-8 ]

A449833[ 154802-74-1 ]

(R)-2-(((Benzyloxy)carbonyl)amino)-3-cyclohexylpropanoic acid

Reason: Optical isomers

Related Functional Groups of
[ 25341-42-8 ]

Amino Acid Derivatives

[ 69901-85-5 ]

Z-D-Chg-OH

Similarity: 0.98

[ 53363-87-4 ]

Z-Leu-OH.DCHA

Similarity: 0.98

[ 69901-75-3 ]

(S)-2-(((Benzyloxy)carbonyl)amino)-2-cyclohexylacetic acid

Similarity: 0.98

[ 405-39-0 ]

Z-Lys(Z)-OH

Similarity: 0.98

[ 1155-62-0 ]

Z-Glu-OH

Similarity: 0.98

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 25341-42-8 ] {[proInfo.proName]}

Quality Control of [ 25341-42-8 ]

Related Doc. of [ 25341-42-8 ]

Product Details of [ 25341-42-8 ]

Safety of [ 25341-42-8 ]

Application In Synthesis of [ 25341-42-8 ]

[ 25341-42-8 ] Synthesis Path-Upstream 1~11

[ 25341-42-8 ] Synthesis Path-Downstream 1~84

Similar Product of [ 25341-42-8 ]

Related Functional Groups of [ 25341-42-8 ]

Amino Acid Derivatives

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Similar Product of
[ 25341-42-8 ]

Related Functional Groups of
[ 25341-42-8 ]